Strimvelis®, EMA approved in 2016, is indicated for adenosine deaminase deficiency (ADA‐SCID), an immunodeficiency disorder caused by mutations in the gene coding for adenosine deaminase (ADA). This evidence concerns the gene ADA and immunodeficiency disease.